Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvalYear |
2015
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01XC65
|
| gptkbp:CASNumber |
1399505-38-4
|
| gptkbp:countryOfOperation |
gptkb:United_States
|
| gptkbp:drugClass |
gptkb:monoclonal_antibody
|
| gptkbp:form |
solution for infusion
|
| gptkbp:genericName |
dinutuximab
|
| https://www.w3.org/2000/01/rdf-schema#label |
Unituxin
|
| gptkbp:indication |
high-risk neuroblastoma in pediatric patients
|
| gptkbp:legalStatus |
Rx-only
|
| gptkbp:manufacturer |
gptkb:United_Therapeutics
|
| gptkbp:mechanismOfAction |
anti-GD2 monoclonal antibody
|
| gptkbp:pregnancyCategory |
not assigned
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
gptkb:capillary_leak_syndrome
pain infection hypotension allergic reactions |
| gptkbp:target |
GD2 antigen
|
| gptkbp:UNII |
8Z6X8Q6P3K
|
| gptkbp:usedFor |
gptkb:neuroblastoma
|
| gptkbp:bfsParent |
gptkb:United_Therapeutics
|
| gptkbp:bfsLayer |
7
|